HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
作者
David S. Siegel,Katja Weisel,Anita Zahlten‐Kumeli,Rohan Medhekar,Sandhya Sapra,Bifeng Ding,Xavier Leleu